Patents
US 11911403 B2: Antisense-induced exon exclusion in type VII collagen
- Granted
- 2024-02-27
- Filed
- 2020-10-26 application 17080363
- Type
- Utility · 8 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.
Source: PVGPATDIS, file of 2026-04-10 (ipg240227.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Dan V. Mourich | Cambridge, MA | 11 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/70 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P17/00 | PVGPATDIS, file of 2026-04-10 |
| C07H | Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids | C07H21/02 | PVGPATDIS, file of 2026-04-10 |
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/113 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
| 2023-01-17 | Correction Corrective assignment to correct the application number17/080,360 previously recorded on reel 062330 frame 0197. assignor(s) hereby confirms the assignment. | MOURICH, DAN V. signed 2018-02-06 | SAREPTA THERAPEUTICS, INC. CAMBRIDGE, MA | 62401/222 | ECORSEXC, file of 2026-09-25 |
| 2023-01-10 | Assignment Assignment of assignor's interest | MOURICH, DAN V. signed 2018-02-06 | SAREPTA THERAPEUTICS, INC. CAMBRIDGE, MA | 62330/197 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.